Wall Street analyst estimates for Bio-Techne Corporation (TECH): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 14 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 26 |
| Avg rating (1-5) | 0.46 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $0.45 | ||
| 2026-08-12 | $0.52 | $0.52 | +0.2% |
| 2026-05-06 | $0.53 | $0.55 | -3.6% |
| 2026-02-04 | $0.46 | $0.43 | +7.0% |
| 2025-11-05 | $0.42 | $0.42 | -0.3% |
| 2025-08-06 | $0.53 | $0.50 | +6.0% |
| 2025-05-07 | $0.56 | $0.51 | +9.8% |
| 2025-02-05 | $0.42 | $0.39 | +7.7% |
Valuation Ratios
| P/E Ratio | 62.41 |
| Price / Book | 5.23 |
| EV / EBITDA | 32.15 |
| Dividend Yield | 0.45% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0M | $643.0M | $714.0M | $738.7M | $931.0M | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Cost of Revenue | $188.5M | $210.8M | $240.5M | $255.5M | $298.2M | $349.1M | $366.9M | $389.3M | $429.4M | $416.0M |
| Gross Profit | $374.5M | $432.1M | $473.5M | $483.2M | $632.9M | $756.5M | $769.8M | $769.7M | $790.3M | $799.1M |
| Research & Development | $53.5M | $55.3M | $62.4M | $65.2M | $70.6M | $87.1M | $92.5M | $96.7M | $99.5M | $94.8M |
| Selling, General & Admin | $199.2M | $240.6M | $264.4M | $240.9M | $289.9M | $339.0M | $352.4M | $393.3M | $415.1M | $452.4M |
| Operating Expenses | $252.8M | $296.0M | $326.8M | $325.8M | $395.6M | $459.9M | $470.9M | $563.0M | $688.0M | $547.2M |
| Operating Income | $121.8M | $136.2M | $125.6M | $157.4M | $237.3M | $296.6M | $298.9M | $206.7M | $102.3M | $251.9M |
| EBITDA | $179.4M | $200.6M | $211.9M | $378.4M | $249.9M | $413.8M | $457.1M | $313.1M | $216.9M | $343.4M |
| Interest Expense | $7.4M | $10.2M | $21.7M | $19.2M | $14.0M | $11.3M | $11.2M | $15.7M | $8.5M | $5.4M |
| Pre-tax Income | $113.2M | $126.0M | $112.0M | $276.5M | $148.2M | $301.4M | $338.7M | $185.7M | $98.5M | $240.7M |
| Income Tax | $35.9M | -$602,000 | $15.9M | $47.2M | $8.6M | $38.3M | $53.2M | $17.6M | $25.1M | $58.8M |
| Net Income | $77.3M | $125.3M | $96.1M | $229.3M | $140.4M | $272.1M | $285.3M | $168.1M | $73.4M | $181.9M |
| EPS | $0.52 | $0.84 | $0.64 | $1.50 | $0.91 | $1.73 | $1.81 | $1.07 | $0.47 | $1.17 |
| EPS (Diluted) | $0.52 | $0.82 | $0.62 | $1.45 | $0.87 | $1.66 | $1.76 | $1.05 | $0.46 | $1.16 |
| Shares Outstanding (Diluted) | $150.0M | $152.2M | $155.6M | $157.6M | $161.9M | $164.1M | $161.9M | $160.8M | $159.7M | $157.0M |
Price
| Price | $72.58 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BMRN · CAI · CORT · EXEL · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of TECH: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks